Faris El-Dahiyat

Evaluating patients’ perceptions regarding generic medicines in Jordan

ObjectiveThe aim of this study was to explore Jordanian patients’ perceptions toward generic medicines and to evaluate their opinions regarding generic substitution.MethodA cross-sectional descriptive study involving Jordanian patients was undertaken, using a self-administrated anonymous questionnaire. The response rate was 80% (n=400/500).ResultsThe study showed that cost of medicines is high according to 83% of the patients. Most patients (92%) preferred to be prescribed the cheapest medicine. Majority of patients (79%) believed that cost should be considered before a drug is prescribed. Most patients (78%) accepted generic substitution and believed that it can provide significant saving. Surveyed patients (78%) agreed that they should have the option of choosing between generic and originator and 74% believed that physicians should give them that choice. These results showed a significant statistical correlation with the monthly income of the patient, percentage cost they pay and number of medicines prescribed (P<0.05).ConclusionThe high cost of medicines in Jordan is believed to be the main driver for choosing generic medicines Furthermore; patients have positive attitudes towards generic medicines. The involvement of patients in the treatment decision would result in more adherence and improvement in health. The insights gained from patients in this study will be useful to health organisations and policy makers to design a robust generic policy to use medicines cost-effectively in Jordan.

Physicians’ perception of generic and electronic prescribing: A descriptive study from Jordan

ObjectivesThe aim of this study was to investigate Jordanian physicians’ perception and attitudes toward generic medicines and generic substitution. It also aimed to examine factors that affect physicians’ pattern of prescribing, and to evaluate their opinion regarding future introduction of Electronic Prescribing (EP) in Jordan.MethodsA cross-sectional descriptive study involving Jordanian physicians working in both public and private sectors was undertaken, using a self-administrated anonymous questionnaire. Frequency tables, cross-tabulation and chi square tests were used for data analysis. The response rate was 75.2% (n = 376/500).ResultsCost was claimed to be an important factor in the prescribing decision for 69.1% of the Jordanian physicians. The majority of physicians (77.4%) claimed that they often prescribe generic medicines. Jordanian physicians predominantly welcomed the implementation of an EP and International Nonproprietary Name (INN) prescribing systems with 92%, and 80.1% respectively. More than two thirds of the physicians (69.4%) accepted generic substitution by pharmacists, with a significant association with their employment sector; physicians who work in the private sector tended to oppose generic substitution compared with physicians who work in the public sector. Physicians mostly (72.1%) opposed that generic substitution should only be allowed upon patient request.ConclusionsJordanian physicians have a positive attitude towards generic medications and high willingness and acceptance of strategies that encourage generic utilisation such as EP, INN prescribing and generic substitution. All these strategies would help reduce the high expenditure on medicines in Jordan. These findings would provide baseline data to policy makers to develop a robust generic policy to achieve greater clinical effectiveness and economic efficiency from medicines prescribing.

Community pharmacists’ perceptions towards generic medicines and their opinions on future generic substitution policy implementation: A descriptive study from Jordan

The aim of this study was to explore Jordanian pharmacists’ perceptions towards generic medicines as well as to evaluate their opinions on generic substitution in order to introduce a future generic substitution policy in Jordan. A cross-sectional descriptive study involving community pharmacists in Amman-Jordan was undertaken, using a self-completed anonymous questionnaire. The sampling unit was community pharmacy, and the sampling frame was list of community pharmacies in Amman (N = 1252). Five hundred pharmacies were randomly selected to participate in this survey, and 294 pharmacists’ responses were collected giving a response rate of 58.8%. The majority of Jordanian pharmacists had a positive view on generic medicines in general with 87.7% of the respondents believing that a generic medicine is bio-equivalents to the originator. Two hundred and sixty-five pharmacists (90.1%) were in favour of implementing a compulsory generic prescribing policy. More than 80% of the pharmacists supported generic substitution in most cases. Generic substitution policy should be implemented; in addition, a formulary of interchangeable medicines must be developed to guide pharmacists’ decision making when performing generic substitution. Jordanian pharmacists were also in favour of introducing a compulsory generic prescribing legislation; however, such policy may have a negative impact on the local industry, as most of the produced medicines are branded generics.

Pharmaceutical Policy in Jordan

For many patients, it is essential to have consistent and regular access to treatment to prevent complications and premature death. In light of this, every country aims to improve availability, affordability and utilisation of essential medicines through the endorsement of good governance and management practices in the pharmaceutical sector. Like other countries, Jordan aims seriously to ensure an uninterrupted availability of essential medicines. This is of particular significance recently after increased stress on the Jordanian pharmaceutical sector as a result of the Syrian refugee crisis. In addition, Jordan has also upgraded its legislation, to govern the conduct of pharmaceutical market, prohibit common forms of misconduct and protect the rights of all parties involved in the pharmaceutical industry. This chapter, thus, explores the main challenges that the pharmaceutical sector may face in the future in Jordan and discusses the current pharmaceutical pricing policy and whether it provides adequate protection to Jordanian patients. Furthermore, this chapter briefly explores the supply and distribution of essential medicines in Jordan and addresses what changes could be made to legislation to ensure the trust and the predictability needed by the relevant parties involved in the pharmaceutical industry in Jordan.